Iron-deficiency Clinical Trial
Official title:
The Effect of Apo- and Holo-Lactoferrin and Dosing Regimen on Iron Absorption From a Maize-based Porridge in Kenyan Infants
The purpose of this study is to measure iron absorption from maize-based porridge fortified with either apo-lactoferrin, holo-lactoferrin or ferrous sulfate and to test whether there is an effect of these. Additionally, iron absorption from maize-based porridge containing 12 mg ferrous sulfate will be measured when consumed every other day versus every third day.
Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia
(IDA), which adversely affects their growth and cognitive development. In-home iron
fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA
by ensuring that the iron needs of infants and young children are met without changing their
traditional diet. Oral iron syrups, typically containing iron as ferrous sulfate, can also be
given to prevent/correct IDA. However, iron absorption from MNPs and iron syrups,
particularly when given with complementary foods high in inhibitors of iron absorption, is
low. Thus, there is a need to find iron formulations with higher bioavailability for use in
African infants. In a recent trial in Kenya, the investigators demonstrated that a prebiotic
could improve iron bioavailability from an iron-containing MNP.
In this study, the investigators plan to assess the human milk compound lactoferrin (Lf) as a
possible enhancer of iron absorption. Lf is an important iron-binding protein in human milk,
which has been thought to be responsible for the high bioavailability of breast-milk iron. It
has many biological functions, including iron absorption, antimicrobial activity,
immunomodulatory effects and stimulatory effect on cell proliferation. Lf has different iron
binding statuses: the iron free form (apo-Lf) and the iron-saturated form (holo-Lf). One of
the two main biological activities of Lf provided by the diet is the control of iron uptake,
which is mediated by the Lf receptor (LFR) as undigested Lf can bind to LFR and facilitate
the uptake of iron. Therefore, Lf may be a nutritional iron source and may enhance iron
absorption in infants. To evaluate the possible role of Lf on the availability of iron, iron
absorption will be measured from bovine Lf (bLf). BLf has GRAS (generally considered as safe)
status by the US Food and Drug Administration.
To optimize iron absorption, timing of supplementation might as well be important. Hepcidin,
a key regulator of systemic iron balance and a single dose of iron can increase hepcidin
levels and potentially inhibit iron absorption from a second dose, consumed close in time to
the first dose. The investigators will conduct two studies, where 24 infants aged 3-14 months
in Msambweni, Kenya, will be enrolled. In study 1, on three alternate mornings, these infants
will consume maize porridge containing a low iron dose (1.5 mg) to compare iron absorption
between meals with apo-Lf, holo-Lf and ferrous sulfate (FeSO4) as a reference; and whether
the addition of either apo- or holo-Lf has a beneficial effect on iron absorption. The
investigators hypothesize that iron absorption will be higher when holo-Lf is present in the
meal compared to apo-Lf. In study 2, the investigators want to compare two different dosing
regimens, in which they measure iron absorption after one-day washout period and after a
two-day washout period, and hypothesize that absorption will be higher after 2 days of
washout.
The data from this project will provide valuable information towards the development of new,
highly bioavailable iron formulations and dosing regimen that is most efficient.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Terminated |
NCT03218384 -
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT03516734 -
Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh
|
N/A | |
Completed |
NCT03572010 -
Stable Iron Isotope Method in HIV+ and HIV- Children
|
N/A | |
Active, not recruiting |
NCT03703726 -
Iron Absorption From Fortified Extruded Rice Using Different Extruding Temperatures.
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Not yet recruiting |
NCT05395468 -
Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.
|
||
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT03353662 -
Sub Regional Micronutrient Survey in Ethiopia
|
||
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT03957057 -
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
|
Phase 3 | |
Completed |
NCT03642223 -
Central and Peripheral Adiposity and Iron Absorption
|
N/A | |
Not yet recruiting |
NCT05407987 -
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
|
Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT04359368 -
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
|
||
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Enrolling by invitation |
NCT05750940 -
Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency
|
||
Recruiting |
NCT05126901 -
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
|
Phase 3 |